Bin Luo1, Lanshan Huang2, Yongyao Gu2, Chunyao Li2, Huiping Lu2, Gang Chen2, Zhigang Peng1, Zhenbo Feng2. 1. Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China. 2. Department of Pathology, The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi Zhuang Autonomous Region, People's Republic of China.
Abstract
Exportin-1 (XPO1) is an essential nuclear export receptor that is involved in the pathogenesis of multiple tumors. However, the role of XPO1 in diffuse large B-cell lymphoma (DLBCL) requires clarification. This study aims to detect XPO1 expression in DLBCL and to explore its relationships with clinicopathologic parameters and prognoses. METHODS: A total of 131 cases of DLBCL and 30 cases of reactive lymphoid hyperplasia were selected for immunohistochemistry to examine XPO1 expression and analyze the relationships of XPO1 expression with clinicopathologic parameters and prognosis. DLBCL datasets downloaded from The Cancer Genome Atlas (TCGA) were used to analyze the mutations, expressions, and clinical values of XPO1 in DLBCL. RESULTS: XPO1 expression was markedly upregulated in DLBCL compared to the reactive lymphoid hyperplasia group (χ2 = 10.734, P = 0.001). High XPO1 expression was associated with an advanced clinical stage (χ2 = 4.036, P = 0.045) and a risky International Prognostic Index (IPI) score (χ2 = 5.301, P = 0.025). Moreover, high XPO1 expression was associated with a lower overall survival rate compared with low expression (P = 0.043). XPO1 was an independent prognostic factor for DLBCL (risk ratio, RR = 3.772, P = 0.006). Furthermore, XPO1 overexpression in DLBCL was correlated with a high IPI score (P = 0.024) in TCGA datasets. CONCLUSION: High XPO1 expression in DLBCL was related to an advanced clinical stage, poor IPI score, and poor prognosis. Thus, XPO1 may be useful for condition identification and prognostic assessment. IJCEP
Exportin-1 (XPO1) is an essential nuclear export receptor that is involved in the pathogenesis of multiple tumors. However, the role of XPO1 in diffuse large B-cell lymphoma (DLBCL) requires clarification. This study aims to detect XPO1 expression in DLBCL and to explore its relationships with clinicopathologic parameters and prognoses. METHODS: A total of 131 cases of DLBCL and 30 cases of reactive lymphoid hyperplasia were selected for immunohistochemistry to examine XPO1 expression and analyze the relationships of XPO1 expression with clinicopathologic parameters and prognosis. DLBCL datasets downloaded from The Cancer Genome Atlas (TCGA) were used to analyze the mutations, expressions, and clinical values of XPO1 in DLBCL. RESULTS:XPO1 expression was markedly upregulated in DLBCL compared to the reactive lymphoid hyperplasia group (χ2 = 10.734, P = 0.001). High XPO1 expression was associated with an advanced clinical stage (χ2 = 4.036, P = 0.045) and a risky International Prognostic Index (IPI) score (χ2 = 5.301, P = 0.025). Moreover, high XPO1 expression was associated with a lower overall survival rate compared with low expression (P = 0.043). XPO1 was an independent prognostic factor for DLBCL (risk ratio, RR = 3.772, P = 0.006). Furthermore, XPO1 overexpression in DLBCL was correlated with a high IPI score (P = 0.024) in TCGA datasets. CONCLUSION: High XPO1 expression in DLBCL was related to an advanced clinical stage, poor IPI score, and poor prognosis. Thus, XPO1 may be useful for condition identification and prognostic assessment. IJCEP
Authors: Joseph D Dekker; Daechan Park; Arthur L Shaffer; Holger Kohlhammer; Wei Deng; Bum-Kyu Lee; Gregory C Ippolito; George Georgiou; Vishwanath R Iyer; Louis M Staudt; Haley O Tucker Journal: Proc Natl Acad Sci U S A Date: 2016-01-19 Impact factor: 11.205
Authors: Jiao Li; Ning Ding; Xiaogan Wang; Lan Mi; Lingyan Ping; Xuan Jin; Yalu Liu; Zhitao Ying; Yan Xie; Weiping Liu; Yuqin Song; Jun Zhu Journal: Cancer Cell Int Date: 2017-07-14 Impact factor: 5.722
Authors: Misako Nagasaka; Mohammad Fahad B Asad; Mohammed Najeeb Al Hallak; Md Hafiz Uddin; Ammar Sukari; Yasmine Baca; Joanne Xiu; Dan Magee; Hirva Mamdani; Dipesh Uprety; Chul Kim; Bing Xia; Stephen V Liu; Jorge J Nieva; Gilberto Lopes; Gerold Bepler; Hossein Borghaei; Michael J Demeure; Luis E Raez; Patrick C Ma; Sonam Puri; W Michael Korn; Asfar S Azmi Journal: Lung Cancer Date: 2021-08-27 Impact factor: 6.081
Authors: Jack G Fisher; Christopher J Walker; Amber Dp Doyle; Peter Wm Johnson; Francesco Forconi; Mark S Cragg; Yosef Landesman; Salim I Khakoo; Matthew D Blunt Journal: Front Oncol Date: 2021-12-01 Impact factor: 6.244
Authors: Josée M Zijlstra; George Follows; Rene-Olivier Casasnovas; Joost S P Vermaat; Nagesh Kalakonda; Sylvain Choquet; Brian Hill; Catherine Thieblemont; Federica Cavallo; Fatima De la Cruz; John Kuruvilla; Nada Hamad; Ulrich Jaeger; Paolo Caimi; Ronit Gurion; Krzysztof Warzocha; Sameer Bakhshi; Juan-Manuel Sancho; Michael Schuster; Miklos Egyed; Fritz Offner; Theodoros P Vassilakopoulos; Priyanka Samal; Matthew Ku; Jenny Xu; Kelly Corona; Kamal Chamoun; Jatin Shah; Miguel Canales; Marie Maerevoet Journal: Cancers (Basel) Date: 2022-02-04 Impact factor: 6.639
Authors: Manman Deng; Mingzhi Zhang; Zijun Y Xu-Monette; Lan V Pham; Alexandar Tzankov; Carlo Visco; Xiaosheng Fang; Govind Bhagat; Feng Zhu; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Eric D Hsi; William W L Choi; Jooryung Huh; Maurilio Ponzoni; Andrés J M Ferreri; Michael B Møller; Benjamin M Parsons; J Han van Krieken; Miguel A Piris; Jane N Winter; Fredrick Hagemeister; Lapo Alinari; Yong Li; Michael Andreeff; Bing Xu; Ken H Young Journal: J Hematol Oncol Date: 2020-11-04 Impact factor: 17.388
Authors: Jithma P Abeykoon; Paul J Hampel; Rebecca L King; Adam J Wood; Melissa C Larson; Kevin E Nowakowski; Saurabh S Zanwar; Surendra Dasari; Gordon J Ruan; Aishwarya Ravindran; Linda E Wellik; Jonas Paludo; Brian K Link; James R Cerhan; Stephen M Ansell; Grzegorz S Nowakowski; Carrie A Thompson; Matthew J Maurer; Kerstin Wenzl; Anne J Novak; Xiaosheng Wu; Thomas M Habermann; Thomas E Witzig Journal: Haematologica Date: 2021-08-01 Impact factor: 9.941